Literature DB >> 29059409

Facilitated Extinction Training to Improve Pharmacotherapy for Smoking Cessation: A Pilot Feasibility Trial.

Thomas H Brandon1,2, Marina Unrod1,2, David J Drobes1,2, Steven K Sutton1,3, Larry W Hawk4, Vani N Simmons1,2, Karen O Brandon1, Richard G Roetzheim1,2, Lauren R Meltzer1, Ralph R Miller5, Shawn P Cahill6.   

Abstract

Introduction: Varenicline reduces smoking satisfaction during the pre-cessation run-in period, which may contribute to extinction of cravings and smoking behavior. Research indicates that efficacy is enhanced when the run-in period is increased from 1 to 4 weeks, providing a longer extinction opportunity. We hypothesized that efficacy could be further enhanced by harnessing basic and applied research on extinction. We developed a pre-cessation extinction-facilitating intervention and tested its feasibility in a pilot trial.
Methods: The facilitated extinction (FE) intervention comprised brief counseling and workbook-recommending strategies to maximize extinction processes during the run-in, including instructions to smoke at a normal rate across contexts and cues, and use of an extinction cue to enhance generalization. Participants were randomly assigned to one of three varenicline interventions: standard (1-week run-in), extended (4-week run-in), and extended + FE. Interventions were delivered prior to the target quit date (TQD). Assessments were conducted in weeks 1 and 4 pre-TQD and 1 and 3 months post-TQD, with focus on feasibility indices.
Results: Recruitment and retention goals were met (N = 58). Treatment satisfaction was high across groups. The majority of FE participants adhered to instructions and maintained their usual smoking rate during the run-in period. Greater decreases in craving and smoking satisfaction were observed among participants in both extended groups versus the standard group (p < .005). Conclusions: Feasibility was demonstrated. Participants adhered to the FE intervention, thereby optimizing the number and variety of extinction trials. Findings support testing the novel FE smoking cessation intervention in a fully powered trial. Implications: This study expands the research on the clinical benefits of extending the pre-cessation run-in period of varenicline. It introduces the hypothesis that further benefit might be achieved by translating basic behavioral research, as well as cue-exposure research and therapy for other disorders, to improve the extinction and generalization processes thought to underlie much of varenicline's effect. A FE intervention was developed and found acceptable to smokers and feasible to implement in a research setting. The study sets the stage for a subsequent randomized controlled trial.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29059409      PMCID: PMC7868958          DOI: 10.1093/ntr/ntx203

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  35 in total

Review 1.  A learning theory perspective on lapse, relapse, and the maintenance of behavior change.

Authors:  M E Bouton
Journal:  Health Psychol       Date:  2000-01       Impact factor: 4.267

Review 2.  Context, ambiguity, and unlearning: sources of relapse after behavioral extinction.

Authors:  Mark E Bouton
Journal:  Biol Psychiatry       Date:  2002-11-15       Impact factor: 13.382

3.  A psychometric evaluation of cigarette stimuli used in a cue reactivity study.

Authors:  Brian L Carter; Jason D Robinson; Cho Y Lam; David W Wetter; Jack Y Tsan; Susan X Day; Paul M Cinciripini
Journal:  Nicotine Tob Res       Date:  2006-06       Impact factor: 4.244

4.  Deepened extinction from compound stimulus presentation.

Authors:  Robert A Rescorla
Journal:  J Exp Psychol Anim Behav Process       Date:  2006-04

5.  Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

Authors:  David Gonzales; Stephen I Rennard; Mitchell Nides; Cheryl Oncken; Salomon Azoulay; Clare B Billing; Eric J Watsky; Jason Gong; Kathryn E Williams; Karen R Reeves
Journal:  JAMA       Date:  2006-07-05       Impact factor: 56.272

6.  The effects of varenicline on stress-induced and cue-induced craving for cigarettes.

Authors:  Lara A Ray; Katy Lunny; Spencer Bujarski; Nathasha Moallem; Jennifer L Krull; Karen Miotto
Journal:  Drug Alcohol Depend       Date:  2013-01-05       Impact factor: 4.492

7.  Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.

Authors:  Mitchell Nides; Cheryl Oncken; David Gonzales; Stephen Rennard; Eric J Watsky; Rich Anziano; Karen R Reeves
Journal:  Arch Intern Med       Date:  2006 Aug 14-28

8.  Effects of 21 days of varenicline versus placebo on smoking behaviors and urges among non-treatment seeking smokers.

Authors:  Rebecca L Ashare; Kathy Z Tang; A Clementina Mesaros; Ian A Blair; Frank Leone; Andrew A Strasser
Journal:  J Psychopharmacol       Date:  2012-06-13       Impact factor: 4.153

9.  Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone.

Authors:  J E Rose; F M Behm; E C Westman; E D Levin; R M Stein; G V Ripka
Journal:  Clin Pharmacol Ther       Date:  1994-07       Impact factor: 6.875

10.  Precessation treatment with nicotine skin patch facilitates smoking cessation.

Authors:  Jed E Rose; Frederique M Behm; Eric C Westman; Prity Kukovich
Journal:  Nicotine Tob Res       Date:  2006-02       Impact factor: 4.244

View more
  3 in total

1.  Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation.

Authors:  Jamie Hartmann-Boyce; Bosun Hong; Jonathan Livingstone-Banks; Hannah Wheat; Thomas R Fanshawe
Journal:  Cochrane Database Syst Rev       Date:  2019-06-05

2.  The co-occurrence of smoking and alcohol use disorder in a hospital-based population: Applying a multimorbidity framework using geographic information system methods.

Authors:  Scott D Siegel; Madeline Brooks; Heather E Ragozine-Bush; Robert A Schnoll; Frank C Curriero
Journal:  Addict Behav       Date:  2021-02-26       Impact factor: 4.591

3.  Using Geospatial Analyses of Linked Electronic Health Records and Tobacco Outlet Data to Address the Social Determinants of Smoking.

Authors:  Scott D Siegel; Madeline M Brooks; Bayo M Gbadebo; James T Laughery
Journal:  Prev Chronic Dis       Date:  2019-11-14       Impact factor: 2.830

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.